詳細検索

詳細検索

お問い合わせ

Rapid Microbiology Testing Market by Product, Method, Application, End User, & Region - Global Forecast to 2031

Rapid Microbiology Testing Market by Product, Method, Application, End User, & Region - Global Forecast to 2031


The market for rapid microbiology testing is projected to grow from USD 5.69 billion in 2026 to USD 9.00 billion by 2031, reflecting a CAGR of 9.6%. Market growth is supported by rising pharmaceut... もっと見る

 

 

出版社
MarketsandMarkets
マーケッツアンドマーケッツ
出版年月
2026年6月16日
電子版価格
US$4,950
シングルユーザーライセンス
ライセンス・価格情報/注文方法はこちら
納期
通常2営業日以内
ページ数
436
図表数
547
言語
英語

英語原文をAIを使って翻訳しています。


 

Summary

The market for rapid microbiology testing is projected to grow from USD 5.69 billion in 2026 to USD 9.00 billion by 2031, reflecting a CAGR of 9.6%. Market growth is supported by rising pharmaceutical and biopharmaceutical production, stringent sterility and contamination control requirements, and expanding use of molecular diagnostics and automated microbiology systems. Additionally, advancements in Polymerase Chain Reaction (PCR), mass spectrometry, and rapid microbial identification technologies are improving laboratory efficiency and supporting broader adoption globally. "By product, reagents & Kits segment to showcase highest CAGR during forecast period” The growth of the reagents & kits segment is primarily driven by the recurring demand for culture media, assay kits, primers, probes, stains, buffers, and antimicrobial susceptibility testing reagents used in rapid microbiology workflows. Rising incidences of infectious diseases and increasing emphasis on sterility assurance and contamination control are accelerating testing volumes across hospitals, pharmaceutical & biotechnology companies, and food testing laboratories. Additionally, expanding adoption of molecular microbiology techniques, automated testing platforms, and rapid PCR-based assays is expected to further drive demand for reagents & kits throughout the forecast period. “By method, growth-based segment to hold the largest share of rapid microbiology testing market in 2026" A growth-based rapid microbiology testing method is likely to dominate the market in 2026 due to its extensive use in pharmaceutical sterility testing, environmental monitoring, food safety testing, and clinical microbiology workflows. Growth-based rapid microbiology methods are widely adopted because they provide reliable detection of viable microorganisms while supporting regulatory compliance and quality assurance requirements. The increasing adoption of automated microbial detection systems, rising demand for faster contamination identification, and growing pharmaceutical and biopharmaceutical manufacturing activities are further driving segment growth. Additionally, the need for rapid product release and improved laboratory efficiency continues to support demand for growth-based testing methods. "Asia Pacific to register fastest growth rate in rapid microbiology testing market during forecast period" The region is witnessing significant growth due to expanding healthcare infrastructure, increasing healthcare expenditure, and rapid modernization of hospitals, diagnostic laboratories, and pharmaceutical manufacturing facilities. Rising prevalence of infectious diseases and growing awareness regarding contamination control and patient safety are increasing the demand for rapid microbial diagnostics across the region. Additionally, increasing investments in biotechnology research, biopharmaceutical production, and laboratory automation are further supporting market expansion. The growing adoption of molecular diagnostics, rapid PCR systems, and automated microbial identification technologies is also contributing to market growth. Major countries driving regional expansion include China, India, Japan, and South Korea. Breakdown of primary participants in the rapid microbiology testing market is as follows: ・ By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) ・ By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%) ・ By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the rapid microbiology testing market are bioMérieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), Thermo Fisher Scientific, Inc. (US), Bruker Corporation (US), QuidelOrtho Corporation (US), Sartorius AG (Germany), Merck KGaA (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Charles River Laboratories International, Inc. (US), Neogen Corporation (US), Bio-Rad Laboratories, Inc. (US), Shimadzu Corporation (Japan), and Rapid Micro Biosystems, Inc. (US). Research Coverage: This research report categorizes the rapid microbiology testing market by product (consumables, instruments, reagents & kits), method (growth-based, cellular component-based, nucleic acid-based, viability-based, and other methods) application (industrial testing, clinical disease diagnosis, and research applications), end user (hospitals, clinical laboratories, & ASCs; pharmaceutical & biotechnology companies; food & beverage companies; environmental & water testing laboratories; and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the rapid microbiology testing market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, solutions, and key strategies, such as partnerships, collaborations, expansions, agreements, product launches, and recent developments in the rapid microbiology testing market. This report covers the competitive analysis of upcoming startups in the rapid microbiology testing ecosystem. Reasons to Buy This Report: The report will help leaders/new entrants in this market by providing information on the closest approximations of revenue for the overall rapid microbiology testing market and its subsegments. This report will help stakeholders understand the competitive landscape and gain deeper insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: ・ Analysis of key drivers (increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases; technological advancements in automated microbiology and MALDI-TOF platforms; growing food safety concerns and rising incidence of foodborne illnesses; increasing R&D activities in microbiology and infectious disease), restraints (high capital investments and low cost-benefit ratio, unfavorable regulatory and reimbursement scenario, shortage of skilled personnel), opportunities (growing demand for rapid microbiology testing in emerging economies, expansion of rapid microbial testing applications), and challenges (operational barriers, high investment for automated microbial identification systems) ・ Product development/innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the rapid microbiology testing market. ・ Market development: Comprehensive information about lucrative markets; the report analyzes the rapid microbiology testing market across varied regions. ・ Market diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the rapid microbiology testing market. ・ Competitive assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like bioMérieux (France), Waters Corporation (US), Danaher Corporation (US), Abbott Laboratories (US), and Thermo Fisher Scientific, Inc. (US).

ページTOPに戻る


Table of Contents

1 INTRODUCTION 39
1.1 STUDY OBJECTIVES 39
1.2 MARKET DEFINITION 39
1.3 STUDY SCOPE 40
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 40
1.3.2 INCLUSIONS AND EXCLUSIONS 41
1.3.3 YEARS CONSIDERED 42
1.3.4 CURRENCY CONSIDERED 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43
2 EXECUTIVE SUMMARY 44
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 44
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 45
2.3 DISRUPTIVE TRENDS SHAPING MARKET 46
2.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS 47
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 48
3 PREMIUM INSIGHTS 49
3.1 RAPID MICROBIOLOGY TESTING MARKET OVERVIEW 49
3.2 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT, 2026 VS. 2031 50
3.3 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD, 2026 VS. 2031 50
3.4 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION, 2026 VS. 2031 51
3.5 RAPID MICROBIOLOGY TESTING MARKET, BY END USER, 2026 VS. 2031 51
3.6 RAPID MICROBIOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Increasing burden of healthcare-associated infections (HAIs), antimicrobial resistance (AMR), and infectious diseases 54
4.2.1.2 Technological advancements in automated microbiology and
MALDI-TOF platforms 55
4.2.1.3 Growing food safety concerns and rising incidence of foodborne illnesses 56
4.2.1.4 Increasing R&D in microbiology and infectious diseases 57

4.2.2 RESTRAINTS 58
4.2.2.1 High capital investments and low cost-benefit ratio 58
4.2.2.2 Unfavorable regulatory and reimbursement scenario 58
4.2.2.3 Shortage of skilled personnel 58
4.2.3 OPPORTUNITIES 59
4.2.3.1 Growing demand for rapid microbiology testing in emerging economies 59
4.2.3.2 Expansion of rapid microbial testing applications 59
4.2.4 CHALLENGES 60
4.2.4.1 Operational barriers 60
4.2.4.2 High investment for automated microbial identification systems 60
4.3 UNMET NEEDS AND WHITE SPACES 61
4.3.1 UNMET NEEDS IN RAPID MICROBIOLOGY TESTING MARKET 61
4.3.2 WHITE SPACE OPPORTUNITIES 62
4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES 63
4.4.1 INTERCONNECTED MARKETS 63
4.4.2 CROSS-SECTOR OPPORTUNITIES 64
4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 65
4.5.1 KEY MOVES AND STRATEGIC FOCUS 65
5 INDUSTRY TRENDS 66
5.1 PORTER’S FIVE FORCES ANALYSIS 66
5.1.1 BARGAINING POWER OF SUPPLIERS 67
5.1.2 BARGAINING POWER OF BUYERS 67
5.1.3 THREAT OF NEW ENTRANTS 67
5.1.4 THREAT OF SUBSTITUTES 67
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMIC INDICATORS 68
5.2.1 INTRODUCTION 68
5.2.2 GDP TRENDS AND FORECAST 68
5.3 SUPPLY CHAIN ANALYSIS 71
5.4 VALUE CHAIN ANALYSIS 72
5.5 ECOSYSTEM ANALYSIS 74
5.5.1 RAPID MICROBIOLOGY TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM 75
5.6 PRICING ANALYSIS 75
5.6.1 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY KEY PLAYER, 2024–2026 76
5.6.2 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY REGION, 2024–2026 76
5.7 TRADE ANALYSIS 77
5.7.1 IMPORT SCENARIO (HS CODE 3822) 78
5.7.2 EXPORT SCENARIO (HS CODE 3822) 78
5.8 KEY CONFERENCES & EVENTS, 2026–2027 79
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 79
5.10 INVESTMENT & FUNDING SCENARIO 80
5.11 CASE STUDY ANALYSIS 81
5.11.1 YOUNGS SEAFOOD ACCELERATED FOOD TESTING WITH VIDAS 81
5.11.2 RAPID MICROBIOLOGICAL METHOD CASE STUDY FOR ADVANCED THERAPY MEDICINAL PRODUCTS 81
5.11.3 RAPID DETECTION METHOD OF BACTERIAL PATHOGENS IN SURFACE WATERS AND NEW RISK INDICATOR FOR WATER PATHOGENIC POLLUTION 82
5.12 IMPACT OF US TARIFFS—RAPID MICROBIOLOGY TESTING MARKET 82
5.12.1 INTRODUCTION 82
5.12.2 KEY TARIFF RATES 83
5.12.3 PRICE IMPACT ANALYSIS 83
5.12.4 IMPACT ON COUNTRIES/REGIONS 84
5.12.4.1 North America 84
5.12.4.2 Europe 84
5.12.4.3 Asia Pacific 84
5.12.5 IMPACT ON END-USE INDUSTRIES 84
5.12.5.1 Hospitals, Clinical Laboratories, and ASCs 84
5.12.5.2 Pharmaceutical & Biotechnology Companies 85
5.12.5.3 Food & Beverage Companies 85
5.12.5.4 Environmental & Water Testing Laboratories 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 KEY EMERGING TECHNOLOGIES 86
6.1.1 AUTOMATED MULTIPLEX PCR SYSTEMS 86
6.1.2 BIOSENSORS 86
6.2 COMPLEMENTARY TECHNOLOGIES 86
6.2.1 OPTICAL IMMUNOSENSORS 86
6.2.2 ELECTROCHEMICAL IMMUNOSENSORS 87
6.3 ADJACENT TECHNOLOGIES 87
6.3.1 DIGITAL PCR (DPCR) 87
6.4 TECHNOLOGY/PRODUCT ROADMAP 87
6.5 PATENT ANALYSIS 88
6.5.1 LIST OF MAJOR PATENTS 89
6.6 FUTURE APPLICATIONS 90
6.7 IMPACT OF AI/GENERATIVE AI ON RAPID MICROBIOLOGY TESTING MARKET 90
6.7.1 INTRODUCTION 90
6.7.2 TOP USE CASES AND MARKET POTENTIAL 91
6.7.3 KEY COMPANIES IMPLEMENTING AI 91
6.7.4 FUTURE OF AI 92
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 93
7.1 REGIONAL REGULATIONS AND COMPLIANCE 93
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
7.1.2 INDUSTRY STANDARDS 95
7.2 SUSTAINABILITY INITIATIVES 96
7.2.1 ENVIRONMENTAL IMPACT AND ECO-FRIENDLY INITIATIVES IN RAPID MICROBIOLOGY TESTING 96
7.2.1.1 Eco-friendly Initiatives 97
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 98
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 99
8.1 DECISION-MAKING PROCESS 99
8.2 KEY STAKEHOLDERS AND BUYING EVALUATION CRITERIA 99
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 99
8.2.2 BUYING CRITERIA 100
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 102
8.5 MARKET PROFITABILITY 103
8.5.1 REVENUE POTENTIAL 103
8.5.2 COST DYNAMICS 104
8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 104
9 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT 106
9.1 INTRODUCTION 107
9.2 INSTRUMENTS 107
9.2.1 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS 112
9.2.1.1 Ease of use compared to conventional identification processes to support market growth 112
9.2.2 MASS SPECTROMETERS 115
9.2.2.1 Rapid results associated with mass spectrometry methods to boost adoption 115
9.2.3 BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS 118
9.2.3.1 Unwanted detection of non-microbial ATP to limit market adoption 118
9.2.4 PCR SYSTEMS 121
9.2.4.1 Growing use of standard, real-time, and qPCR for rapid microbial testing to support growth 121
9.2.5 CYTOMETERS 124
9.2.5.1 Ability to detect viable organisms to favor market growth 124
9.2.6 ACTIVE AIR SAMPLERS 127
9.2.6.1 Convenience and ease of use to drive demand for active air samplers 127
9.2.7 OTHER INSTRUMENTS 130
9.3 REAGENTS & KITS 133
9.3.1 STERILITY TESTING REAGENTS & KITS 136
9.3.1.1 Increasing adoption of BET assays to propel market growth 136
9.3.2 OTHER REAGENTS & KITS 139
9.4 CONSUMABLES 142
9.4.1 DEVELOPMENT OF AUTOMATED ZONE READERS AND DISPENSERS TO DRIVE MARKET GROWTH 142
10 RAPID MICROBIOLOGY TESTING MARKET: VOLUME ANALYSIS 146
10.1 INTRODUCTION 146
10.2 GLOBAL: VOLUME OF MALDI-TOF MS MICROBIAL IDENTIFICATION SYSTEM
INSTALLED BASE 146
11 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD 147
11.1 INTRODUCTION 148
11.2 GROWTH-BASED RAPID MICROBIOLOGY TESTING 149
11.2.1 RISING DEMAND FOR GROWTH-BASED TESTING TO DRIVE MARKET 149
11.3 CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING 152
11.3.1 HIGH SENSITIVITY, ACCURACY, AND SPECIFICITY OF CELLULAR COMPONENT-BASED METHODS TO BOOST MARKET 152
11.4 NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING 155
11.4.1 HIGH ACCURACY ASSOCIATED WITH NUCLEIC ACID-BASED METHODS TO FAVOR MARKET GROWTH 155
11.5 VIABILITY-BASED RAPID MICROBIOLOGY TESTING 158
11.5.1 NEAR REAL-TIME DETECTION AND IMPROVED ACCURACY TO DRIVE DEMAND 158
11.6 OTHER METHODS 161
12 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION 165
12.1 INTRODUCTION 166
12.2 INDUSTRIAL TESTING 166
12.2.1 FOOD & BEVERAGE TESTING 170
12.2.1.1 Stringent quality control and quality assurance processes to drive market growth 170
12.2.2 PHARMACEUTICAL & BIOLOGICAL DRUG TESTING 173
12.2.2.1 Improved regulatory scenario for drug development to support market growth 173
12.2.3 ENVIRONMENTAL TESTING 177
12.2.3.1 Growing focus on environmental monitoring to boost segmental growth 177
12.2.4 COSMETIC & PERSONAL CARE PRODUCTS TESTING 180
12.2.4.1 Growing use of rapid microbiology testing to determine the presence of microbes favors market growth 180
12.2.5 OTHER INDUSTRIAL TESTING APPLICATIONS 184

12.3 CLINICAL DISEASE DIAGNOSIS 187
12.3.1 HIGH BURDEN OF INFECTIOUS DISEASES AND HEALTHCARE-ASSOCIATED INFECTIONS TO PROPEL MARKET GROWTH 187
12.4 RESEARCH 191
12.4.1 INCREASING NUMBER OF EPIDEMIOLOGY-BASED RESEARCH STUDIES TO DRIVE MARKET GROWTH 191
13 RAPID MICROBIOLOGY TESTING MARKET, BY END USER 195
13.1 INTRODUCTION 196
13.2 HOSPITALS, CLINICAL LABORATORIES, AND ASCS 196
13.2.1 INCREASING PATIENT VOLUME AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 196
13.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 200
13.3.1 STRINGENT GMP AND CONTAMINATION CONTROL REQUIREMENTS TO DRIVE TESTING DEMAND 200
13.4 FOOD & BEVERAGE COMPANIES 203
13.4.1 STRINGENT FOOD SAFETY REGULATIONS AND QUALITY CONTROL TO SUPPORT MARKET GROWTH 203
13.5 ENVIRONMENTAL & WATER TESTING LABORATORIES 206
13.5.1 GROWING FOCUS ON WATER SAFETY AND ENVIRONMENTAL MONITORING TO DRIVE DEMAND 206
13.6 OTHER END USERS 210
14 RAPID MICROBIOLOGY TESTING MARKET, BY REGION 214
14.1 INTRODUCTION 215
14.2 NORTH AMERICA 215
14.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 216
14.2.2 US 221
14.2.2.1 Increasing prevalence of infectious diseases to drive market 221
14.2.3 CANADA 225
14.2.3.1 Supportive government initiatives and increased research funding to boost market 225
14.3 EUROPE 230
14.3.1 EUROPE: MACROECONOMIC OUTLOOK 230
14.3.2 GERMANY 234
14.3.2.1 Favorable government policies to propel market 234
14.3.3 FRANCE 239
14.3.3.1 Favorable healthcare reforms and investments in diagnostic infrastructure to drive market 239
14.3.4 UK 242
14.3.4.1 Emphasis on food contamination monitoring and hygiene controls to drive market 242
14.3.5 ITALY 246
14.3.5.1 Improved healthcare services and better disease surveillance to support market growth 246
14.3.6 SPAIN 251
14.3.6.1 Water monitoring mandate to boost market growth 251
14.3.7 RUSSIA 255
14.3.7.1 Strengthening water quality surveillance and outbreak response drives adoption in Russia 255
14.3.8 REST OF EUROPE 259
14.4 ASIA PACIFIC 263
14.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 263
14.4.2 CHINA 267
14.4.2.1 Increasing government focus on disease prevention to drive market 267
14.4.3 JAPAN 272
14.4.3.1 Stringent safety laws and foodborne outbreaks to fuel uptake 272
14.4.4 INDIA 276
14.4.4.1 High target patient population to boost demand 276
14.4.5 SOUTH KOREA 280
14.4.5.1 Favorable government initiatives for medical tourism to support market growth 280
14.4.6 AUSTRALIA 284
14.4.6.1 Favorable healthcare automation techniques to support market growth 284
14.4.7 REST OF ASIA PACIFIC 288
14.5 LATIN AMERICA 291
14.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 292
14.5.2 BRAZIL 297
14.5.2.1 Improving healthcare infrastructure and stringent regulations to fuel market 297
14.5.3 MEXICO 301
14.5.3.1 Increasing prevalence of HIV to drive market 301
14.5.4 REST OF LATIN AMERICA 304
14.6 MIDDLE EAST & AFRICA 308
14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 310
14.6.2 SAUDI ARABIA 314
14.6.2.1 Increasing focus on healthcare automation to drive market 314
14.6.3 UNITED ARAB EMIRATES (UAE) 318
14.6.3.1 Improvements in healthcare infrastructure to support market growth 318
14.6.4 REST OF MIDDLE EAST & AFRICA 322
15 COMPETITIVE LANDSCAPE 326
15.1 INTRODUCTION 326
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 326
15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN RAPID MICROBIOLOGY TESTING MARKET 326
15.3 REVENUE ANALYSIS, 2023–2025 328

15.4 MARKET SHARE ANALYSIS, 2025 328
15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 329
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 331
15.5.1 STARS 331
15.5.2 EMERGING LEADERS 331
15.5.3 PERVASIVE PLAYERS 331
15.5.4 PARTICIPANTS 331
15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 333
15.5.5.1 Company footprint 333
15.5.5.2 Region footprint 334
15.5.5.3 Product footprint 335
15.5.5.4 Application footprint 335
15.5.5.5 End-user footprint 336
15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 336
15.6.1 PROGRESSIVE COMPANIES 336
15.6.2 RESPONSIVE COMPANIES 336
15.6.3 DYNAMIC COMPANIES 337
15.6.4 STARTING BLOCKS 337
15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 338
15.6.5.1 Detailed list of key startups/SMEs 338
15.6.5.2 Competitive benchmarking of startups/SMEs 339
15.7 COMPANY VALUATION & FINANCIAL METRICS 340
15.7.1 FINANCIAL METRICS 340
15.7.2 COMPANY VALUATION 340
15.8 BRAND/PRODUCT COMPARISON 341
15.9 COMPETITIVE SCENARIO 341
15.9.1 PRODUCT LAUNCHES & APPROVALS 341
15.9.2 DEALS 342
15.9.3 EXPANSIONS 343
16 COMPANY PROFILES 344
16.1 KEY PLAYERS 344
16.1.1 BIOMÉRIEUX 344
16.1.1.1 Business overview 344
16.1.1.2 Products offered 346
16.1.1.3 Recent developments 348
16.1.1.3.1 Product launches & approvals 348
16.1.1.3.2 Deals 349
16.1.1.3.3 Other developments 350
16.1.1.4 MnM view 350
16.1.1.4.1 Right to win 350

16.1.1.4.2 Strategic choices 351
16.1.1.4.3 Weaknesses & competitive threats 351
16.1.2 WATERS CORPORATION 352
16.1.2.1 Business overview 352
16.1.2.2 Products offered 354
16.1.2.3 Recent developments 355
16.1.2.3.1 Product approvals 355
16.1.2.3.2 Deals 355
16.1.2.4 MnM view 356
16.1.2.4.1 Right to win 356
16.1.2.4.2 Strategic choices 356
16.1.2.4.3 Weaknesses & competitive threats 356
16.1.3 DANAHER CORPORATION 357
16.1.3.1 Business overview 357
16.1.3.2 Products offered 358
16.1.3.3 Recent developments 360
16.1.3.3.1 Product approvals 360
16.1.3.3.2 Deals 360
16.1.3.4 MnM view 361
16.1.3.4.1 Right to win 361
16.1.3.4.2 Strategic choices 361
16.1.3.4.3 Weaknesses & competitive threats 361
16.1.4 ABBOTT LABORATORIES 362
16.1.4.1 Business overview 362
16.1.4.2 Products offered 363
16.1.4.3 Recent developments 365
16.1.4.3.1 Product approvals 365
16.1.4.4 MnM view 365
16.1.4.4.1 Right to win 365
16.1.4.4.2 Strategic choices 365
16.1.4.4.3 Weaknesses & competitive threats 365
16.1.5 THERMO FISHER SCIENTIFIC INC. 366
16.1.5.1 Business overview 366
16.1.5.2 Products offered 367
16.1.5.3 Recent developments 369
16.1.5.3.1 Product launches 369
16.1.5.3.2 Deals 369
16.1.5.4 MnM view 370
16.1.5.4.1 Right to win 370
16.1.5.4.2 Strategic choices 370
16.1.5.4.3 Weaknesses & competitive threats 370

16.1.6 BRUKER CORPORATION 371
16.1.6.1 Business overview 371
16.1.6.2 Products offered 373
16.1.6.3 Recent developments 374
16.1.6.3.1 Product launches & approvals 374
16.1.6.3.2 Deals 374
16.1.7 QUIDELORTHO CORPORATION 375
16.1.7.1 Business overview 375
16.1.7.2 Products offered 376
16.1.7.3 Recent developments 378
16.1.7.3.1 Product launches & approvals 378
16.1.7.3.2 Deals 378
16.1.7.3.3 Expansions 379
16.1.8 SARTORIUS AG 380
16.1.8.1 Business overview 380
16.1.8.2 Products offered 382
16.1.9 MERCK KGAA 383
16.1.9.1 Business overview 383
16.1.9.2 Products offered 385
16.1.9.3 Recent developments 385
16.1.9.3.1 Product launches & approvals 385
16.1.10 F. HOFFMANN-LA ROCHE LTD 386
16.1.10.1 Business overview 386
16.1.10.2 Products offered 387
16.1.10.3 Recent developments 388
16.1.10.3.1 Product launches & approvals 388
16.1.10.3.2 Deals 388
16.1.11 CHARLES RIVER LABORATORIES, INC. 389
16.1.11.1 Business overview 389
16.1.11.2 Products offered 390
16.1.11.3 Recent developments 391
16.1.11.3.1 Product launches 391
16.1.11.3.2 Deals 391
16.1.12 NEOGEN CORPORATION 392
16.1.12.1 Business overview 392
16.1.12.2 Products offered 393
16.1.12.3 Recent developments 394
16.1.12.3.1 Product launches 394
16.1.13 BIO-RAD LABORATORIES, INC. 395
16.1.13.1 Business overview 395
16.1.13.2 Products offered 396
16.1.13.3 Recent developments 397
16.1.13.3.1 Product launches & approvals 397
16.1.13.3.2 Deals 397
16.1.14 SHIMADZU CORPORATION 398
16.1.14.1 Business overview 398
16.1.14.2 Products offered 400
16.1.14.3 Recent developments 400
16.1.14.3.1 Expansions 400
16.1.15 RAPID MICRO BIOSYSTEMS, INC. 401
16.1.15.1 Business overview 401
16.1.15.2 Products offered 402
16.1.15.3 Recent developments 403
16.1.15.3.1 Deals 403
16.2 OTHER PLAYERS 404
16.2.1 DON WHITLEY SCIENTIFIC LIMITED 404
16.2.2 GRADIENTECH 405
16.2.3 RQMICRO AG 406
16.2.4 COLIFAST AS 407
16.2.5 HYGIENA LLC 408
16.2.6 COPAN DIAGNOSTICS INC. 409
16.2.7 PERKINELMER INC. 410
16.2.8 HARDY DIAGNOSTICS 411
16.2.9 CHARM SCIENCES 412
16.2.10 R-BIOPHARM 413
17 RESEARCH METHODOLOGY 414
17.1 RESEARCH DATA 414
17.2 RESEARCH APPROACH 414
17.2.1 SECONDARY RESEARCH 415
17.2.1.1 Key data from secondary sources 416
17.2.2 PRIMARY DATA 417
17.2.2.1 Primary sources 417
17.2.2.2 Key data from primary sources 418
17.2.2.3 Key industry insights 419
17.3 MARKET SIZE ESTIMATION 420
17.3.1 BOTTOM-UP APPROACH 421
17.3.1.1 Approach 1: Company revenue estimation approach 421
17.3.1.2 Approach 2: Presentations of companies and primary interviews 422
17.3.1.3 Growth forecast 422
17.3.2 TOP-DOWN APPROACH 423
17.4 MARKET BREAKDOWN AND DATA TRIANGULATION 424

17.5 MARKET SHARE ANALYSIS 425
17.6 RESEARCH ASSUMPTIONS 425
17.6.1 PARAMETRIC ASSUMPTIONS 425
17.6.2 GROWTH RATE ASSUMPTIONS 426
17.7 RESEARCH LIMITATIONS 426
17.8 RISK ASSESSMENT 426
18 APPENDIX 427
18.1 DISCUSSION GUIDE 427
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 432
18.3 CUSTOMIZATION OPTIONS 434
18.4 RELATED REPORTS 434
18.5 AUTHOR DETAILS 435

ページTOPに戻る



List of Tables/Graphs

TABLE 1 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV, ALL AGES,
2010, 2023, AND 2024 (MILLION PEOPLE) 55
TABLE 2 TOTAL TUBERCULOSIS INCIDENCE, BY REGION, 2024 55
TABLE 3 US: FOOD RECALLS AND REASONS, 2025 56
TABLE 4 US: FOOD RECALLS, BY SPECIES, 2025 57
TABLE 5 RAPID MICROBIOLOGY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 67
TABLE 6 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 68
TABLE 7 NORTH AMERICA: MACROECONOMIC INDICATORS 69
TABLE 8 EUROPE: MACROECONOMIC INDICATORS 70
TABLE 9 ASIA PACIFIC: MACROECONOMIC INDICATORS 70
TABLE 10 LATIN AMERICA: MACROECONOMIC INDICATORS 70
TABLE 11 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 71
TABLE 12 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY KEY PLAYER, 2024–2026 (USD) 76
TABLE 13 AVERAGE SELLING PRICE OF RAPID MICROBIOLOGY TESTING PRODUCTS,
BY REGION, 2024–2026 (USD) 77
TABLE 14 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS,
BY COUNTRY, 2020–2024 (USD MILLION) 78
TABLE 15 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS,
BY COUNTRY, 2020–2024 (USD MILLION) 78
TABLE 16 RAPID MICROBIOLOGY TESTING MARKET: KEY CONFERENCES
AND EVENTS, 2026–2027 79
TABLE 17 US-ADJUSTED RECIPROCAL TARIFF RATES 83
TABLE 18 LIST OF MAJOR PATENTS PERTAINING TO RAPID MICROBIOLOGY TESTING MARKET, 2023–2025 89
TABLE 19 KEY COMPANIES IMPLEMENTING AI IN RAPID MICROBIOLOGY TESTING MARKET 92
TABLE 20 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 21 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 93
TABLE 22 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 94
TABLE 23 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 95
TABLE 24 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 95
TABLE 25 GLOBAL STANDARDS IN THE RAPID MICROBIOLOGY TESTING MARKET 96
TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 100
TABLE 27 KEY BUYING CRITERIA, BY PRODUCT 100
TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 101
TABLE 29 RAPID MICROBIOLOGY TESTING MARKET: UNMET NEEDS IN VARIOUS
END-USE INDUSTRIES 102
TABLE 30 RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 107
TABLE 31 KEY PRODUCTS IN RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET 108
TABLE 32 RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 109
TABLE 33 RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 109
TABLE 34 NORTH AMERICA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 35 EUROPE: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 110
TABLE 36 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 37 LATIN AMERICA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 111
TABLE 38 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 112
TABLE 39 AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 113
TABLE 40 NORTH AMERICA: AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 113
TABLE 41 EUROPE: AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 114
TABLE 42 ASIA PACIFIC: AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 114
TABLE 43 LATIN AMERICA: AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 115
TABLE 44 MIDDLE EAST & AFRICA: AUTOMATED MICROBIAL IDENTIFICATION & ANTIMICROBIAL SUSCEPTIBILITY TESTING SYSTEMS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 115
TABLE 45 MASS SPECTROMETERS MARKET, BY REGION, 2024–2031 (USD MILLION) 116
TABLE 46 NORTH AMERICA: MASS SPECTROMETERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 116
TABLE 47 EUROPE: MASS SPECTROMETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 48 ASIA PACIFIC: MASS SPECTROMETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 117
TABLE 49 LATIN AMERICA: MASS SPECTROMETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 118
TABLE 50 MIDDLE EAST & AFRICA: MASS SPECTROMETERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 118
TABLE 51 BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET,
BY REGION, 2024–2031 (USD MILLION) 119
TABLE 52 NORTH AMERICA: BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 119
TABLE 53 EUROPE: BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 54 ASIA PACIFIC: BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 120
TABLE 55 LATIN AMERICA: BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 56 MIDDLE EAST & AFRICA: BIOLUMINESCENCE & FLUORESCENCE-BASED DETECTION SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 121
TABLE 57 PCR SYSTEMS MARKET, BY REGION, 2024–2031 (USD MILLION) 122
TABLE 58 NORTH AMERICA: PCR SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 122
TABLE 59 EUROPE: PCR SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 60 ASIA PACIFIC: PCR SYSTEMS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 123
TABLE 61 LATIN AMERICA: PCR SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 62 MIDDLE EAST & AFRICA: PCR SYSTEMS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 124
TABLE 63 CYTOMETERS MARKET, BY REGION, 2024–2031 (USD MILLION) 125
TABLE 64 NORTH AMERICA: CYTOMETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 125
TABLE 65 EUROPE: CYTOMETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 66 ASIA PACIFIC: CYTOMETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 126
TABLE 67 LATIN AMERICA: CYTOMETERS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 127
TABLE 68 MIDDLE EAST & AFRICA: CYTOMETERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 127
TABLE 69 ACTIVE AIR SAMPLERS MARKET, BY REGION, 2024–2031 (USD MILLION) 128
TABLE 70 NORTH AMERICA: ACTIVE AIR SAMPLERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 128
TABLE 71 EUROPE: ACTIVE AIR SAMPLERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 72 ASIA PACIFIC: ACTIVE AIR SAMPLERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 129
TABLE 73 LATIN AMERICA: ACTIVE AIR SAMPLERS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 130
TABLE 74 MIDDLE EAST & AFRICA: ACTIVE AIR SAMPLERS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 130
TABLE 75 OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY REGION, 2024–2031 (USD MILLION) 131
TABLE 76 NORTH AMERICA: OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 77 EUROPE: OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 78 ASIA PACIFIC: OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 79 LATIN AMERICA: OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 80 MIDDLE EAST & AFRICA: OTHER RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 81 RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 134
TABLE 82 RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY REGION, 2024–2031 (USD MILLION) 134
TABLE 83 NORTH AMERICA: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 134
TABLE 84 EUROPE: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 85 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 86 LATIN AMERICA: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 87 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING REAGENTS
& KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 88 STERILITY TESTING REAGENTS & KITS MARKET, BY REGION,
2024–2031 (USD MILLION) 137
TABLE 89 NORTH AMERICA: STERILITY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 90 EUROPE: STERILITY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 91 ASIA PACIFIC: STERILITY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 138
TABLE 92 LATIN AMERICA: STERILITY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 93 MIDDLE EAST & AFRICA: STERILITY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 139
TABLE 94 OTHER RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY REGION, 2024–2031 (USD MILLION) 140
TABLE 95 NORTH AMERICA: OTHER RAPID MICROBIOLOGY TESTING REAGENTS
& KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 96 EUROPE: OTHER RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 97 ASIA PACIFIC: OTHER RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 98 LATIN AMERICA: OTHER RAPID MICROBIOLOGY TESTING REAGENTS
& KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 99 MIDDLE EAST & AFRICA: OTHER RAPID MICROBIOLOGY TESTING REAGENTS
& KITS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 100 RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET,
BY REGION, 2024–2031 (USD MILLION) 143
TABLE 101 NORTH AMERICA: RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 102 EUROPE: RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 103 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 104 LATIN AMERICA: RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 105 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 106 GLOBAL: MALDI-TOF MS MICROBIAL IDENTIFICATION SYSTEM INSTALLED BASE VOLUME, 2024–2031 (UNITS) 146
TABLE 107 RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 148
TABLE 108 TYPES OF TECHNOLOGIES USED IN VARIOUS RAPID MICROBIOLOGY TESTING METHODS 148
TABLE 109 GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY REGION, 2024–2031 (USD MILLION) 150
TABLE 110 NORTH AMERICA: GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 150
TABLE 111 EUROPE: GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 112 ASIA PACIFIC: GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 151
TABLE 113 LATIN AMERICA: GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 114 MIDDLE EAST & AFRICA: GROWTH-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 152
TABLE 115 CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY REGION, 2024–2031 (USD MILLION) 153
TABLE 116 NORTH AMERICA: CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 117 EUROPE: CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 118 ASIA PACIFIC: CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 119 LATIN AMERICA: CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 120 MIDDLE EAST & AFRICA: CELLULAR COMPONENT-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 121 NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY REGION, 2024–2031 (USD MILLION) 156
TABLE 122 NORTH AMERICA: NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 156
TABLE 123 EUROPE: NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 124 ASIA PACIFIC: NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 125 LATIN AMERICA: NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 126 MIDDLE EAST & AFRICA: NUCLEIC ACID-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 127 VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY REGION, 2024–2031 (USD MILLION) 159
TABLE 128 NORTH AMERICA: VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 129 EUROPE: VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 130 ASIA PACIFIC: VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 131 LATIN AMERICA: VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 132 MIDDLE EAST & AFRICA: VIABILITY-BASED RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 133 OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET,
BY REGION, 2024–2031 (USD MILLION) 162
TABLE 134 NORTH AMERICA: OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 135 EUROPE: OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 136 ASIA PACIFIC: OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 163
TABLE 137 LATIN AMERICA: OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 138 MIDDLE EAST & AFRICA: OTHER RAPID MICROBIOLOGY TESTING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 139 RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 166
TABLE 140 RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 167
TABLE 141 RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY REGION, 2024–2031 (USD MILLION) 167
TABLE 142 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 143 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY COUNTRY, 2024–2031 (USD MILLION) 168
TABLE 144 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 145 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 169
TABLE 146 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 147 RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE TESTING,
BY REGION, 2024–2031 (USD MILLION) 171
TABLE 148 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 149 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD &
BEVERAGE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 150 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD &
BEVERAGE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 151 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD &
BEVERAGE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 152 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173
TABLE 153 RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL &
BIOLOGICAL DRUG TESTING, BY REGION, 2024–2031 (USD MILLION) 174
TABLE 154 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOLOGICAL DRUG TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 155 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOLOGICAL DRUG TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 156 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOLOGICAL DRUG TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 157 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOLOGICAL DRUG TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 158 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOLOGICAL DRUG TESTING, BY COUNTRY,
2024–2031 (USD MILLION) 177
TABLE 159 RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING,
BY REGION, 2024–2031 (USD MILLION) 178
TABLE 160 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 161 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 162 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 163 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 164 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 165 QUALITY REGULATIONS & STANDARDS FOR COSMETICS & PERSONAL CARE 181
TABLE 166 RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY REGION, 2024–2031 (USD MILLION) 181
TABLE 167 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 168 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 169 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 170 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 171 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR COSMETIC & PERSONAL CARE PRODUCT TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 184
TABLE 172 RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 185
TABLE 173 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 174 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 175 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 176 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 177 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER INDUSTRIAL TESTING APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 178 RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS,
BY REGION, 2024–2031 (USD MILLION) 188
TABLE 179 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 180 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 181 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 182 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 183 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR CLINICAL DISEASE DIAGNOSIS, BY COUNTRY, 2024–2031 (USD MILLION) 191
TABLE 184 RAPID MICROBIOLOGY TESTING MARKET FOR RESEARCH,
BY REGION, 2024–2031 (USD MILLION) 192
TABLE 185 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 186 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 187 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 188 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR RESEARCH,
BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 189 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET
FOR RESEARCH, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 190 RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 196
TABLE 191 RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, & ASCS, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 192 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, AND ASCS, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 193 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, AND ASCS, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 194 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, AND ASCS, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 195 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, AND ASCS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 196 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR HOSPITALS, CLINICAL LABORATORIES, AND ASCS, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 197 RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 198 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 201
TABLE 199 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 200 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 201 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 202 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 203
TABLE 203 RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES,
BY REGION, 2024–2031 (USD MILLION) 204
TABLE 204 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 205 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 206 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 207 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 208 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR FOOD & BEVERAGE COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 209 RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 210 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 211 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 208
TABLE 212 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 213 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 214 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR ENVIRONMENTAL & WATER TESTING LABORATORIES, BY COUNTRY,
2024–2031 (USD MILLION) 210
TABLE 215 RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 211
TABLE 216 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 217 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS,
BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 218 ASIA PACIFIC: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 219 LATIN AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 220 MIDDLE EAST & AFRICA: RAPID MICROBIOLOGY TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 221 RAPID MICROBIOLOGY TESTING MARKET, BY REGION, 2024–2031 (USD MILLION) 215
TABLE 222 NORTH AMERICA: MACROECONOMIC INDICATORS 217
TABLE 223 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 224 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 218
TABLE 225 NORTH AMERICA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 226 NORTH AMERICA: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 227 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET,
BY METHOD, 2024–2031 (USD MILLION) 220
TABLE 228 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 220
TABLE 229 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING, BY TYPE, 2024–2031 (USD MILLION) 221
TABLE 230 NORTH AMERICA: RAPID MICROBIOLOGY TESTING MARKET,
BY END USER, 2024–2031 (USD MILLION) 221
TABLE 231 US: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 222
TABLE 232 US: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 233 US: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 223
TABLE 234 US: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 224
TABLE 235 US: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 224
TABLE 236 US: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 237 US: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 225
TABLE 238 CANADA: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 226
TABLE 239 CANADA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 240 CANADA: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 227
TABLE 241 CANADA: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 228
TABLE 242 CANADA: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 228
TABLE 243 CANADA: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 229
TABLE 244 CANADA: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 229
TABLE 245 EUROPE: MACROECONOMIC INDICATORS 231
TABLE 246 EUROPE: RAPID MICROBIOLOGY TESTING MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 231
TABLE 247 EUROPE: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 231
TABLE 248 EUROPE: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 249 EUROPE: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 232
TABLE 250 EUROPE: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 233
TABLE 251 EUROPE: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 233
TABLE 252 EUROPE: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 253 EUROPE: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 234
TABLE 254 GERMANY: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 235
TABLE 255 GERMANY: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 256 GERMANY: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 236
TABLE 257 GERMANY: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 237
TABLE 258 GERMANY: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 237
TABLE 259 GERMANY: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 238
TABLE 260 GERMANY: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 238
TABLE 261 FRANCE: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 239
TABLE 262 FRANCE: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 263 FRANCE: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 264 FRANCE: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 241
TABLE 265 FRANCE: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 241
TABLE 266 FRANCE: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 242
TABLE 267 FRANCE: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 242
TABLE 268 UK: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 244
TABLE 269 UK: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 244
TABLE 270 UK: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 271 UK: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 245
TABLE 272 UK: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 245
TABLE 273 UK: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 274 UK: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 246
TABLE 275 ITALY: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 247
TABLE 276 ITALY: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 277 ITALY: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 278 ITALY: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 249
TABLE 279 ITALY: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 249
TABLE 280 ITALY: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 250
TABLE 281 ITALY: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 250
TABLE 282 SPAIN: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 251
TABLE 283 SPAIN: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 284 SPAIN: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 252
TABLE 285 SPAIN: RAPID MICROBIOLOGY TESTING MARKET, BY METHOD,
2024–2031 (USD MILLION) 253
TABLE 286 SPAIN: RAPID MICROBIOLOGY TESTING MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 253
TABLE 287 SPAIN: RAPID MICROBIOLOGY TESTING MARKET FOR INDUSTRIAL TESTING,
BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 288 SPAIN: RAPID MICROBIOLOGY TESTING MARKET, BY END USER,
2024–2031 (USD MILLION) 254
TABLE 289 RUSSIA: RAPID MICROBIOLOGY TESTING MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 255
TABLE 290 RUSSIA: RAPID MICROBIOLOGY TESTING INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 291 RUSSIA: RAPID MICROBIOLOGY TESTING REAGENTS & KITS MARKET

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

MarketsandMarkets社の Medical Devices分野 での最新刊レポート


よくあるご質問


MarketsandMarkets社はどのような調査会社ですか?


マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。


詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

 

2026/07/10 10:26

163.14 円

186.97 円

221.62 円

ページTOPに戻る